PRESS RELEASE

published on 07/17/2023 at 16:00 from Arix Bioscience PLC (isin : GB00BD045071)

Holding(s) in Company

Arix Bioscience PLC (ARIX)
Holding(s) in Company

17-Jul-2023 / 15:00 GMT/BST

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BD045071

Issuer Name

ARIX BIOSCIENCE PLC

UK or Non-UK Issuer

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Ruffer LLP

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

14-Jul-2023

6. Date on which Issuer notified

17-Jul-2023

7. Total positions of person(s) subject to the notification obligation

.	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	4.977220	0.000000	4.977220	6440000
Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BD045071	6440000	0	4.977220	0.000000
Sub Total 8.A	6440000		4.977220%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

Ruffer LLP now controls the voting rights over 6,440,000 shares (less than 5% of the voting rights) of Arix Bioscience plc which are held by the discretionary clients of Ruffer LLP and its subsidiaries (the voting of which is all controlled by Ruffer LLP).
This change from 5% to less than 5% is due to the sale of 80,000 shares by Ruffer LLP on 14 July 2023.

12. Date of Completion

17-Jul-2023

13. Place Of Completion

Ruffer LLP

Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


ISIN:	GB00BD045071
Category Code:	HOL
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	2.3. Major shareholding notifications
Sequence No.:	258222
EQS News ID:	1681769


End of Announcement	EQS News Service

See all Arix Bioscience PLC news